A surrogate approach investigated the neutralizing effect of bevacizumab on circulating VEGF using a VEGF-dependent cell line subjected to sera of cancer patients treated with bevacizumab suggested potential to predict clinical benefit 164. This evidence concerns the gene VEGFA and cancer.